Ripple News: First XRP ETF Approval Could Happen by June 25

Crypto ETFs have been a big topic lately, as major asset managers continue adjusting their filings. Some important deadlines are now getting close. ProShares and Franklin Templeton have both set key dates in June, bringing hope that the SEC may finally approve them.

In a new filing dated June 10, ProShares asked the SEC to move the launch date for its Solana and XRP ETFs to June 25, 2025. If approved, the SEC would need to make a clear decision by that day, instead of delaying again.

Spot XRP and Solana ETFs Inch Closer

This means spot Solana and XRP ETFs could be approved as early as June 25, 2025. Franklin Templeton also has an XRP ETF decision coming on June 17, so approval might happen this month. The filings for these ETFs were first sent in on January 17, 2025. Right now, no spot XRP ETF has been approved, but ProShares and Franklin Templeton could be the first.

The SEC is still being careful about crypto ETFs. It has been worried about keeping investors safe, stopping market cheating, and making sure the market is strong enough. These concerns have caused delays before. The updated filings show that the companies are working hard to follow the rules and get approval.

• Also Read :
•   XRP Withdrawals Temporarily Suspended on Binance; Price Falls, Users React
• ,

Is “Altcoin ETF Summer” Here?

Bloomberg ETF analysts predict an 85% Chance of XRP ETF Approval. Analyst Eric Balchunas, in a recent X post, hinted at a possible “Altcoin ETF Summer,” with Solana likely taking the lead. He referred to a report from analyst James Seyfart that gives updated odds for all the upcoming spot crypto ETFs. It’s a sign that the ETF market for altcoins could be heating up soon.

The odds of an XRP ETF approval on the Polymarket Prediction platform are currently at 87%. 

XRP’s chances for ETF approval are looking stronger than ever. With key decisions coming in June and chances as high as 87%, this could be a big step forward for XRP and the crypto market.

FAQs